ADPKD: Symptoms, Diagnostic Tests, and Treatment
ADPKD presents with bilateral kidney cysts causing progressive kidney enlargement, hypertension, abdominal pain, and liver cysts, diagnosed primarily by ultrasound in at-risk adults or MRI for prognostication, with tolvaptan as the only FDA-approved disease-modifying treatment for rapidly progressive disease. 1
Clinical Manifestations
Renal Symptoms
The hallmark presentation includes:
- Multiple bilateral kidney cysts with progressive kidney enlargement
- Hypertension (often early-onset, before significant kidney function decline)
- Abdominal fullness and pain from massive kidney enlargement
- Gross hematuria from cyst hemorrhage
- Cyst infections (fever, flank pain, elevated inflammatory markers)
- Nephrolithiasis (kidney stones)
- Progressive chronic kidney disease leading to kidney failure, typically after age 40 for PKD1 mutations (50s) or age 70 for PKD2 mutations 1
Extrarenal Manifestations
- Polycystic liver disease (most common extrarenal finding)
- Intracranial aneurysms (requires screening in high-risk patients)
- Cardiovascular abnormalities
- Reduced quality of life from chronic pain and disease burden 1, 2
The severity correlates with: PKD1 truncating mutations > PKD1 nontruncating > PKD2, male sex, obesity, and high salt intake 1
Diagnostic Tests
For Adults at Risk (Positive Family History)
Start with abdominal ultrasound as the first-line screening test 1:
Age-specific ultrasound diagnostic criteria:
- Ages 15-39 years: ≥3 total cysts confirms diagnosis; ≤1 cyst rules out ADPKD
- Ages 40-59 years: ≥2 cysts in each kidney confirms diagnosis; ≤2 total cysts rules out ADPKD
- Age ≥60 years: ≥4 cysts in each kidney confirms diagnosis 1
If ultrasound is equivocal or atypical features present:
- Proceed to MRI of kidneys (or CT with/without contrast)
- MRI criteria for ages 16-40 years: >10 total cysts confirms diagnosis; <5 total cysts rules out ADPKD 1
Genetic testing is indicated when:
- Few kidney cysts with uncertain diagnosis
- Variable intrafamilial disease severity
- Discordant imaging and kidney function
- No family history but cysts detected
- Evaluating young (<30 years) living kidney donors
- Family planning/preimplantation diagnosis 1
For Incidentally Detected Cysts (No Known Family History)
Follow diagnostic algorithm with kidney MRI and/or genetic testing to distinguish ADPKD from mimicking conditions (HNF1B-related disease, Alagille syndrome, COL4A disorders, autosomal dominant tubulointerstitial kidney disease) 1
Prognostic Assessment
Use Mayo Imaging Classification (MIC) to predict kidney function decline and timing of kidney failure 1:
- Measures height-adjusted total kidney volume by MRI or CT
- Stratifies typical imaging (Class 1) patients into 5 groups (1A-1E) indicating accelerating decline
- Only valid for PKD1/PKD2 mutations, not minor genes
- Ultrasound-determined kidney volume and length are less precise alternatives
Treatment
Disease-Modifying Therapy
Tolvaptan (vasopressin V2-receptor antagonist) is the only FDA-approved treatment for ADPKD and should be used early in patients at high risk of kidney failure 1, 2, 3:
Indications for tolvaptan:
- Rapidly progressive ADPKD
- High-risk patients based on Mayo Imaging Classification (Class 1C-1E)
- PKD1 truncating mutations with early kidney enlargement
Critical caveat: Tolvaptan requires monitoring for hepatotoxicity with regular liver function tests 3
Blood Pressure Management
Target aggressive blood pressure control in ADPKD patients:
- Evidence supports lower BP targets than standard CKD management
- Renin-angiotensin system blockade (ACE inhibitors or ARBs) is recommended 1
Symptomatic Management
Cyst complications:
- Cyst hemorrhage: Supportive care, CT abdomen/pelvis with contrast for diagnosis 4
- Cyst infection: Prolonged antibiotics (lipophilic agents penetrate cysts better: fluoroquinolones, trimethoprim-sulfamethoxazole)
- Nephrolithiasis: Standard stone management
- Chronic pain: Multimodal pain management, consider cyst aspiration/sclerosis for large symptomatic cysts
Polycystic liver disease:
- Somatostatin analogues have been studied but are not FDA-approved for this indication
- Surgical options (cyst fenestration, liver resection, transplantation) for severe symptomatic cases
Kidney Failure Management
When kidney failure develops:
- Kidney replacement therapy (dialysis or transplantation)
- ADPKD patients are generally good transplant candidates
- Native nephrectomy may be needed if massive kidney size causes symptoms or space constraints
What Does NOT Work
Multiple therapies tested in randomized controlled trials have failed to show benefit: statins, pioglitazone, sirolimus, everolimus, bosutinib. Do not use these for ADPKD-specific treatment 1
Common Pitfalls
Do not use Mayo Imaging Classification for minor gene mutations (ALG5, ALG9, GANAB, IFT140, DNAJB11, NEK8) - prognostic validity only established for PKD1/PKD2 1
Do not diagnose ADPKD based solely on a minor gene variant when clinical diagnosis is uncertain - phenotype must match 1
Ultrasound criteria do not apply to minor gene families - genetic testing is essential in these cases 1
Provide genetic counseling before and after testing - address implications for family planning, insurance, and psychological impact 1
Screen for intracranial aneurysms in patients with family history of aneurysms or high-risk occupations (pilots, etc.) 2